SEC Filing · 25
Palatin Technologies, Inc.
PTNNASDAQEQUITYCurrent
SEC Filing
Company context
We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Current securities
As-filed source
As filedOpen full document ↗